Abstract
ObjectiveWe previously established concentrated autologous bone marrow aspirate transplantation as a one-step, lowly invasive, joint-preserving surgical technique for treating osteonecrosis of the femoral head. The objectives of this study were to identify factors that may predict the mesenchymal stem cell (MSC) count in bone marrow aspirate, concentrated using our method, and to clarify etiology related differences in the number of MSCs in concentrated bone marrow aspirate.ResultsThe MSC counts per 106 nucleated cells before concentration in the steroid, alcohol, and trauma groups were 2.31 ± 2.96, 2.58 ± 2.30, and 1.95 ± 1.85, respectively. The MSC counts per 106 nucleated cells after concentration were 3.23 ± 3.41, 3.30 ± 2.83, and 2.56 ± 1.98 cells, respectively. The MSC concentration rates in the steroid, alcohol, and trauma groups were 7.15 ± 5.62, 5.08 ± 1.96, and 8.23 ± 4.82 times, respectively. None of the differences were significant. Multiple regression analysis revealed that MSC count was related to the total bone marrow aspirated, peripheral blood platelet count, and nucleated cell count in the initial aspiration.
Highlights
We developed a simple and efficient method for collecting mesenchymal stem cells (MSCs) by centrifuging bone marrow aspirate to concentrate and extract a buffcoat layer containing MSCs, which may be used to treat osteonecrosis of the femoral head (ONFH) [1, 2]
The nucleated cell counts in the steroid, alcohol, and trauma groups in peripheral blood were 6.9 ± 2.9 × 103/μL, 5.9 ± 1.4 × 103/
Since 2003, our department has used a simplified method for concentrating bone marrow aspirate [1] and a one-step surgical procedure involving transplanting into the area of necrosis
Summary
We developed a simple and efficient method for collecting mesenchymal stem cells (MSCs) by centrifuging bone marrow aspirate to concentrate and extract a buffcoat layer containing MSCs, which may be used to treat osteonecrosis of the femoral head (ONFH) [1, 2]. Hernigou et al [4, 5] reported positive outcomes in the treatment of ONFH and nonunion by concentrating close to 600 progenitor cells/mL of iliac bone marrow aspirate to approximately 2500 cells/ mL using a cell separator. As we did not perform cell culture or predictive screenings, we could not calculate the MSC count in bone marrow aspirate during the procedure. The objectives of this study were to identify predictive factors of and clarify etiology-related differences in MSC count in concentrated bone marrow aspirate
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
